Physician profile
Millicent Animley
NPI 1760104913
$3,810.47
in general payments reported to CMS, 2019-2025
24 companies · $3,792 in 2025
The $3,792 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $18.30 · 2025: $3,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.47 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.06 | 2025 | |
| Janssen Biotech, INC. | $622.31 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $390.58 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $300.23 | 2025 | Rezdiffra |
| Qol Medical, LLC | $230.38 | 2025 | Sucraid |
| Pfizer INC. | $219.89 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.58 | 2025 | Xifaxan |
| Braintree Laboratories, INC. | $150.31 | 2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $118.28 | 2025 | Iqirvo |
| Lilly USA, LLC | $110.18 | 2025 | Omvoh |
| Genzyme Corporation | $104.16 | 2025 | |
| Intercept Pharmaceuticals, INC. | $89.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $87.93 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $86.63 | 2025 | Vowst |
| Gilead Sciences, INC. | $84.88 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $53.25 | 2025 | Ibsrela |
| Novo Nordisk INC | $44.32 | 2025 | Wegovy |
| Digestive Care, INC. | $35.50 | 2025 | Pertzye |
| Celltrion USA INC. | $34.14 | 2025 | Vegzelma |
| Orphalan INC | $24.83 | 2025 | Cuvrior |
| Amgen INC. | $21.00 | 2025 | Uplizna |
| Biocon Biologics INC | $19.63 | 2025 | Yesintek |
| Pharmacosmos Therapeutics INC. | $17.70 | 2025 | Monoferric |
| Alnylam Pharmaceuticals INC. | $15.45 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millicent Animley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.